Selective HDAC-3 inhibitors have also been shown to up-regulate the expression of PD-L1 in B-cell lymphoma, suggesting that HDAC-3 may be one of the key inhibitors mediating PD-L1 transcription in B-cell lymphoma (138). This evidence concerns the gene CD274 and B-cell non-Hodgkin lymphoma.